Anticryptococcal activity by alveolar macrophages from rats treated with cortisone acetate during different periods of time

Mycopathologia

Volumn 136, Issue 1, 1996, Pages 1-8

  Gross, N T ^a,b   Chinchilla, M ^b   Camner, P ^c   Jarstrand, C ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

alveolar macrophages; cortisone acetate; Cryptococcus neoformans; oxidative metabolism; phagocytosis

Indexed keywords

EID: 0030426604     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00436653     Document Type: Article

References (17)

1. Henson DJ, Hill AR. Cryptococcal pneumonia: a fulminant presentation. Am J Med Sci 1984; 288: 221-222.
2. Schröter GPJ, Temple DR, Husberg BS, Weil R, Starzl TE. Cryptococcosis after renal transplantation: Report often cases. Surgery 1976; 79(3): 268-277.
3. Wilson TS, Fleming WA, Robinson FLJ, Nicholl B. Cryptococcal meningitis associated with steroid therapy. J Clin Path 1970; 23: 657-663.
4. Perfect JR, Durack DT, Gallis HA. Cryptococcemia. Medicine 1983; 62: 98-109.
5. Bernstein B, Flomenberg P, Letzer D. Disseminated cryptococcal disease complicating steroid therapy for Pneumocystis carinii pneumonia in a patient with AIDS. South Med J 1994; 87(4): 537-538.
6. White MH, Armstrong D. Cryptococcosis. Infec Dis Clin North Am 1994; 8(2): 383-398.
7. Ellis DH, Pfeiffer TJ. Ecology, life cycle, and infectious propagule of Cryptococcus neoformans. Lancet 1990; 336: 923-925.
8. Rozenbaum R, Goncalves AJR. Clinical epidemiological study of 171 cases of Cryptococcosis. Clin Infect Dis 1994; 18: 369-380.
9. Neilson JB, Fromtling RA, Bulmer GS. Cryptococcus neoformans: size range of infectious particles from aerosolized soil. Infect Immun 1977; 17: 634-638.
10. Powell KE, Dahl BA, Weeks RJ, Tosh FE. Airbone Cryptococcus neoformans: particles from pigeon excreta compatible with alveolar deposition. J Infect Dis 1972; 125: 412-415.
11. Fromtling RA, Shadomy HJ. An overview of macrophage-fungal interactions. Mycophathologia 1986; 93: 77-93.
12. Kozel TR, Pfromer GST. Role of the capsule in phagocytosis of Cryptococcus neoformans. Rev Infect Dis 1988; 10(2): S436-S439.
13. Bolanos B, Mitchel TG. Phagocytosis of Cryptococcus neoformans by rat alveolar macrophages. J Med Vet Mycol 1989; 27: 203-217.
14. Levitz SM, DiBenedetto DJ. Paradoxical role of capsule in murine bronchoalveolar macrophage-raediated killing of Cryptococcus neoformans. J Immunol 1989; 142(2): 659-665.
15. Yasuoka A, Kohno S, Yamada H, Kaku M, Koga H. Influence of molecular sizes of Cryptococcus neoformans capsular polysacharide on phagocytosis. Microbiol Immunol 1994; 38(11): 851-856.
16. Gudewicz PW. The effects of cortisone therapy on lung macrophage host defense function and glucose metabolism. Circ Shock 1981; 8(1): 95-103.
17. Waldorf AR, Levitz SM, Diamond RD. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis 1984; 150(5): 752-760.